Entero-insular axis in children with simple obesity

Pediatric Endocrinology, Diabetes and Metabolism

Volumn 15, Issue 2, 2009, Pages 63-69

  Tomasik, Przemysław J ^a   Sztefko, Krystyna ^a   Starzyk, Jerzy ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Adolescence; Cholecystokinin; Gastric inhibitory peptide; Glucagon; Glucagon like peptide 1; Insulin; Pancreatic polypeptide

Indexed keywords

CHOLECYSTOKININ; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; PANCREAS POLYPEPTIDE;

ADOLESCENT; ARTICLE; AXIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE ACTION; HUMAN; MEASUREMENT; OBESITY; RADIOIMMUNOASSAY; BLOOD; GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PSYCHOPHYSIOLOGY;

ADOLESCENT; CHOLECYSTOKININ; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; OBESITY; SATIETY RESPONSE;

EID: 84904841523     PISSN: 1234625X     EISSN: 20838441     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Sabin M.A., Shield J.P.: Childhood obesity. Front. Horm. Res., 2008, 36, 85-96.
2. Mercer J.G.: Models and mechanisms of energy balance regulation in the young. Proc. Nutr. Soc., 2008, 67, 327-333.
3. Creutzfeldt W.: The incretin concept today. Diabetologia, 1979, 16, 75-85.
4. Flatt R.P.: Pancreatic B-cells as mediators of metabolic effects of regulatory peptides. Biochem. Soc. Trans., 1996, 24, 570-575.
5. Creutzfeldt W., Ebert R.: The incretin concept. Adv. Metab. Disorders., 1988, 11, 333-367.
6. Ranganath L.R.: The entero-insular axis: implications for human metabolism. Clin. Chem. Lab. Med., 2008, 46, 43-56.
7. Weiss R., Dziura J., Burgert T.S., Tamborlane W.V., Taksali S.E., Yeckel C.W., Allen K., Lopes M., Savoye M., Morrison J., Sherwin R.S., Caprio S.: Obesity and the metabolic syndrome in children and adolescents. N. Engl. J. Med., 2004, 350, 2362-2374.
8. Glueck C.J., Morrison J.A., Wang P.: Insulin resistance, obesity, hypofibrinolysis, hyperandrogenism, and coronary heart disease risk factors in 25 pre-perimenarchal girls age < or =14 years, 13 with precocious puberty, 23 with a first-degree relative with polycystic ovary syndrome. J. Pediatr. Endocrinol. Metab., 2008, 21, 973-984.
9. Ekelund U., Anderssen S., Andersen L.B., Riddoch C.J., Sardinha L.B., Luan J., Froberg K., Brage S.: Prevalence and correlates of the metabolic syndrome in a population-based sample of European youth. Am. J. Clin. Nutr., 2009, 89, 90-96.
10. Cali A.M., Caprio S.: Obesity in children and adolescents. J. Clin. Endocrinol. Metab., 2008, 93, S31-36.
11. Stock S., Leichner P., Wong A.C., Ghatei M.A., Kieffer T.J., Bloom S.R., Chanoine J.P.: Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J. Clin. Endocrinol. Metab., 2005, 90, 2161-2168.
12. Chanoine J.P., Mackelvie K.J., Barr S.I., Wong A.C., Meneilly G.S., Elahi D.H.: GLP-1 and appetite responses to a meal in lean and overweight adolescents following exercise. Obesity, 2008, 16, 202-204.
13. McHugh P., Moran T.: The stomach, cholecystokinin and satiety. Fed. Proc., 1986, 45, 1384-1390.
14. Flint A., Raben A., Ersboll A.K., Holst J.J., Astrup A.: The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int. J. Obes. Relat. Metab. Disord., 2001, 25, 781-792
15. Kastin A.J., Akerstrom V., Pan W.: Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci., 2002, 18, 7-14.
16. Wilmshurst P., Crawley J.C.: The measurement of gastric transit time in obese subjects using 24Na and the effects of energy content and guar gum on gastric emptying and satiety. Br. J. Nutr., 1980, 44, 1-6.
17. Elahi D., Egan J.M., Shannon R.P., Meneilly G.S., Khatri A., Habener J.F., Andersen D.K.: GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity, 2008, 16, 1501-1509
18. Ranganath L.R.: Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. J. Clin. Pathol., 2008, 61, 401-409.
19. McClean P.L., Gault V.A., Irwin N., McCluskey J.T., Flatt P.R.: Daily administration of the GIPR antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP. Diabetes Obes. Metab., 2008;10: 336-342.
20. Rushakoff R., Goldfine I., Carter J., Liddle R.: Physiological concentrations of cholecystokinin stimulate aminoacid induced insulin release in humans. J. Clin. Endocrinol. Metab., 1987, 65, 395-401.
21. Karlsson S., Ahrén B.: Cholecystokinin and the regulation of insulin secretion. Scand. J. Gastroentrol., 1992, 27, 161-165.
22. Konturek S., Tasler J., Bilski J., de Jong A.J., Jansen J.B., Lamers C.B.: Physiological role and localization of cholecystokinin release in dogs. Am. J. Physiol., 1986, 250, G391-397.